{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:44:58Z","timestamp":1791895498337,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In recent years, the usefulness of androgen receptor axis\u2010targeted agents (ARATs) such as abiraterone, enzalutamide, and apalutamide for the upfront treatment of metastatic hormone\u2010sensitive prostate cancer (mHSPC) has been demonstrated. However, it remains unclear which patients would truly benefit from these treatments. Furthermore, intraductal carcinoma of the prostate (IDC\u2010P) is a known poor prognostic factor in patients with prostate cancer. We investigated the association between the presence of IDC\u2010P and response to therapy in patients with mHSPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective analysis included 318 patients with mHSPC who received treatment at Nagoya University and its 12 affiliated institutions between 2014 and 2021. Their biopsy specimens were evaluated for the presence of IDC\u2010P. The patients were classified according to their first\u2010line treatment into the ARAT (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009100, receiving a combination of androgen\u2010deprivation therapy [ADT] and ARAT) or conventional therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009218, receiving ADT with or without standard antiandrogen agents) group. We compared the overall survival (OS) and second progression\u2010free survival (PFS2) between the ARAT and conventional groups according to the presence of IDC\u2010P to evaluate whether presence of IDC\u2010P predicts the response to each treatment. PFS2 was defined as the period from mHSPC diagnosis to disease progression on second\u2010line treatment or death. Propensity score matching with one\u2010to\u2010one nearest\u2010neighbor matching was used to minimize the potential effects of selection bias and confounding factors. The clinicopathological variables of the patients were well\u2010balanced after propensity score matching.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most patients in the ARAT (79%) and conventional therapy (71%) groups were ICD\u2010P positive. In the propensity score\u2010matched cohort, the OS and PFS2 of IDC\u2010P\u2010positive patients were significantly longer in the ARAT group than in the conventional group (OS: hazard ratio [HR], 0.36;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047; PFS2: HR, 0.30;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In contrast, no difference in OS and PFS2 was observed between the ARAT and conventional groups in IDC\u2010P\u2010negative patients (OS: HR, 1.09;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.920; PFS2: HR, 0.40;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.264).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings highlight a high prevalence of IDC\u2010P among patients with mHSPC and suggest that IDC\u2010P positivity may be a reliable indicator that ARAT should be implemented as first\u2010line treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.24462","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T10:39:58Z","timestamp":1669286398000},"page":"307-315","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone\u2010sensitive prostate cancer"],"prefix":"10.1002","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6256-4352","authenticated-orcid":false,"given":"Yushi","family":"Naito","sequence":"first","affiliation":[{"name":"Department of Urology Nagoya University Graduate School of Medicine Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3454-3658","authenticated-orcid":false,"given":"Masashi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology Nagoya University Graduate School of Medicine Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideji","family":"Kawanishi","sequence":"additional","affiliation":[{"name":"Department of Urology Aichi Medical University Hospital Nagakute Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology Toyohashi Municipal Hospital Toyohashi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitoshi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Urology Chubu Rosai Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hirabayashi","sequence":"additional","affiliation":[{"name":"Department of Urology Japanese Red Cross Nagoya Daiichi Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology Narita Memorial Hospital Toyohashi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7823-2600","authenticated-orcid":false,"given":"Yoshihisa","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Department of Urology Nagoya University Graduate School of Medicine Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology Japan Community Healthcare Organization Chukyo Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemori","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Urology Meitetsu Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Nishikimi","sequence":"additional","affiliation":[{"name":"Department of Urology Japanese Red Cross Nagoya Daini Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuya","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Urology Kariya Toyota General Hospital Kariya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Urology National Hospital Organization Nagoya Medical Center Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Urology Yokkaichi Municipal Hospital Yokkaichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yojiro","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Urology Tosei General Hospital  Seto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4855-4366","authenticated-orcid":false,"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology Aichi Medical University Hospital  Nagakute Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3657"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06201.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.030"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.003"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.028"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001290"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.146"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23831"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3976-z"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15530"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23484"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199607000-00003"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14722"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.100"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23958"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.03.013"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP8EL5FTZSOBIH"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14043"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23942"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14970"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv346"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5801"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19520"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5535"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.06.015"},{"key":"e_1_2_9_32_1","unstructured":"ClinicalTrials.gov.U.S. National Library of Medicine. Accessed June 18 2022.https:\/\/clinicaltrials.gov\/ct2\/results?pg=1%26load=cart%26id=NCT04497844%2BOR%2BNCT04493853"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800702"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.06.017"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.24462","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T03:17:20Z","timestamp":1692501440000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.24462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/pros.24462"],"URL":"https:\/\/doi.org\/10.1002\/pros.24462","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"2022-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}